IER5L

Summary

IER5L (immediate early response 5 like, HGNC:23679) is a protein-coding gene on chromosome 9q34.11, encoding Immediate early response gene 5-like protein (Q5T953).

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_203434

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23679
Approved symbol	IER5L
Name	immediate early response 5 like
Location	9q34.11
Locus type	gene with protein product
Status	Approved
Aliases	bA247A12.2
Ensembl gene	ENSG00000188483
Ensembl biotype	protein_coding
Entrez	389792

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000372491

RefSeq mRNA: 1 — MANE Select: NM_203434 NM_203434

CCDS: CCDS43888

Canonical transcript exons

ENST00000372491 — 1 exons

Exon	Start	End
ENSE00001457937	129175552	129178261

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 94.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 111.6698 / max 1617.1585, expressed in 1807 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102734	111.6698	1807

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	94.11	gold quality
vena cava	UBERON:0004087	92.60	silver quality
left ventricle myocardium	UBERON:0006566	90.85	gold quality
descending thoracic aorta	UBERON:0002345	90.03	gold quality
cardiac muscle of right atrium	UBERON:0003379	89.89	gold quality
endocervix	UBERON:0000458	89.51	gold quality
tendon of biceps brachii	UBERON:0008188	88.47	gold quality
ascending aorta	UBERON:0001496	87.80	gold quality
thoracic aorta	UBERON:0001515	87.71	gold quality
aorta	UBERON:0000947	87.37	gold quality
popliteal artery	UBERON:0002250	87.19	gold quality
tibial artery	UBERON:0007610	87.15	gold quality
pericardium	UBERON:0002407	87.03	gold quality
decidua	UBERON:0002450	86.37	gold quality
cortical plate	UBERON:0005343	85.71	gold quality
left coronary artery	UBERON:0001626	84.99	gold quality
metanephros cortex	UBERON:0010533	84.92	gold quality
coronary artery	UBERON:0001621	84.89	gold quality
trachea	UBERON:0003126	84.62	silver quality
right coronary artery	UBERON:0001625	84.59	gold quality
pancreatic ductal cell	CL:0002079	84.23	silver quality
peritoneum	UBERON:0002358	83.97	gold quality
omental fat pad	UBERON:0010414	83.97	gold quality
ectocervix	UBERON:0012249	83.89	gold quality
left uterine tube	UBERON:0001303	83.60	gold quality
upper arm skin	UBERON:0004263	83.52	gold quality
seminal vesicle	UBERON:0000998	83.29	gold quality
right ovary	UBERON:0002118	83.08	gold quality
adipose tissue of abdominal region	UBERON:0007808	83.07	gold quality
saphenous vein	UBERON:0007318	82.95	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	21.52
E-ANND-3	yes	6.19
E-GEOD-137537	yes	6.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting IER5L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-765	99.84	68.24	2442

Literature-anchored findings (GeneRIF, showing 2)

• The results suggest that IER2, IER5, and IER5L proteins are target protein-specific regulators of PP2A (protein phosphatase 2A) activity and modulate cell proliferation through CDC25A (cell division cycle 25A protein) activity. (PMID:30599213)
• Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients. (PMID:38552564)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ier5l	ENSDARG00000054906
mus_musculus	Ier5l	ENSMUSG00000089762
rattus_norvegicus	Ier5l	ENSRNOG00000073054

Paralogs (2): IER2 (ENSG00000160888), IER5 (ENSG00000162783)

Protein

Protein identifiers

Immediate early response gene 5-like protein — Q5T953 (reviewed: Q5T953)

All UniProt accessions (1): Q5T953

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the IER family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5T953-1	1	yes
Q5T953-2	2

RefSeq proteins (1): NP_982258* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008653	IER	Family

Pfam: PF05760

UniProt features (10 total): region of interest 3, compositionally biased region 3, splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T953-F1	58.00	0.09

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 159 (showing top): E2F_Q4, E2F_Q4_01, E2F4DP1_01, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, AP2_Q3, FOXO1_01, USF_C, CAGCTG_AP4_Q5, CEBP_Q2, E2F1DP1_01, E2F_Q3, E2F1DP2_01, GATA3_01, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

450 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IER5L	SLC35F3	Q8IY50	425
IER5L	PGM2L1	Q6PCE3	419
IER5L	TM9SF4	Q92544	414
IER5L	NAA25	Q14CX7	403
IER5L	PGBD4	Q96DM1	402
IER5L	PHAX	Q9H814	398
IER5L	ANO8	Q9HCE9	385
IER5L	ZBTB2	Q8N680	383
IER5L	GET3	O43681	381
IER5L	CELSR3	Q9NYQ7	376
IER5L	RBBP8NL	Q8NC74	371
IER5L	PUS7L	Q9H0K6	365
IER5L	CCDC90B	Q9GZT6	365
IER5L	YOD1	Q5VVQ6	360
IER5L	C10orf71	Q711Q0	354

IntAct

6 interactions, top by confidence:

A	B	Type	Score
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R2B	MYO9A	psi-mi:“MI:0914”(association)	0.640
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (5): IER5L (Affinity Capture-RNA), IER5L (Affinity Capture-MS), IER5L (Affinity Capture-MS), IER5L (Affinity Capture-RNA), IER5L (Affinity Capture-RNA)

ESM2 similar proteins: A6NEQ2, A6NJT0, A7MB34, A8MYZ6, G3UXB3, O02755, O02756, O08934, O35392, O70218, O70220, O89113, P16443, P17542, P17676, P22091, P49716, P50548, P82976, P97830, Q00322, Q00911, Q01822, Q03484, Q10586, Q15270, Q32PF6, Q5PQP0, Q5T953, Q5TGY3, Q5VY09, Q60843, Q60925, Q64305, Q6PAL7, Q70KY4, Q7RTS3, Q80VF6, Q8WY41, Q96RK0

Diamond homologs: B7SXM5, O89113, P17950, Q5PQP0, Q5T953, Q5VY09, Q66IT9, Q6NYT3, Q6P7D3, Q6PBC9, Q99J55, Q9BTL4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	77
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

32 predictions. Top by Δscore:

Variant	Effect	Δscore
9:129176972:C:CT	acceptor_gain	0.5200
9:129176571:C:CC	acceptor_gain	0.4900
9:129176818:C:A	donor_gain	0.4500
9:129176973:A:T	acceptor_gain	0.4400
9:129176836:C:A	donor_gain	0.4100
9:129176966:C:CT	acceptor_gain	0.4000
9:129176959:G:T	acceptor_gain	0.3700
9:129176570:A:AC	acceptor_gain	0.3500
9:129176762:T:TA	donor_gain	0.3200
9:129176594:G:GT	acceptor_gain	0.2800
9:129176595:T:TT	acceptor_gain	0.2800
9:129176972:C:T	acceptor_gain	0.2800
9:129177127:T:TA	donor_gain	0.2700
9:129176967:G:T	acceptor_gain	0.2600
9:129176958:C:T	acceptor_gain	0.2500
9:129176197:G:T	acceptor_gain	0.2400
9:129176759:C:A	donor_gain	0.2400
9:129177118:T:TA	donor_gain	0.2400
9:129176569:CA:C	acceptor_gain	0.2300
9:129176597:G:GT	acceptor_gain	0.2300
9:129177106:T:TA	donor_gain	0.2300
9:129176568:TCA:T	acceptor_gain	0.2200
9:129176569:CAC:C	acceptor_gain	0.2200
9:129176730:AGCC:A	donor_gain	0.2200
9:129177825:CG:C	donor_gain	0.2200
9:129176730:AGC:A	donor_gain	0.2100
9:129176958:C:CT	acceptor_gain	0.2100
9:129177121:T:TA	donor_gain	0.2100
9:129177147:G:A	donor_gain	0.2100
9:129176570:ACTAC:A	acceptor_gain	0.2000

AlphaMissense

2582 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:129176841:G:C	F404L	1.000
9:129176841:G:T	F404L	1.000
9:129176843:A:G	F404L	1.000
9:129176851:A:T	I401N	1.000
9:129176862:C:A	W397C	1.000
9:129176862:C:G	W397C	1.000
9:129176864:A:G	W397R	1.000
9:129176864:A:T	W397R	1.000
9:129176962:A:G	F364S	1.000
9:129176974:A:G	F360S	1.000
9:129176983:A:T	I357N	1.000
9:129176986:A:G	L356S	1.000
9:129177274:T:A	D260V	1.000
9:129177277:A:G	L259P	1.000
9:129177277:A:T	L259Q	1.000
9:129177280:T:A	D258V	1.000
9:129177280:T:C	D258G	1.000
9:129177283:A:G	L257P	1.000
9:129177926:C:G	A43P	1.000
9:129177931:C:G	R41P	1.000
9:129177934:A:G	L40P	1.000
9:129177934:A:T	L40H	1.000
9:129177949:A:G	L35P	1.000
9:129177952:A:G	L34P	1.000
9:129177952:A:T	L34H	1.000
9:129177954:G:C	N33K	1.000
9:129177954:G:T	N33K	1.000
9:129177957:C:A	K32N	1.000
9:129177957:C:G	K32N	1.000
9:129177958:T:A	K32M	1.000

dbSNP variants (sampled 300 via entrez): RS1000239133 (9:129177641 C>A,T), RS1000489864 (9:129178070 G>A,C), RS1001110391 (9:129177020 C>A), RS1001190649 (9:129178576 C>T), RS1001567367 (9:129178271 C>T), RS1002191369 (9:129179879 A>T), RS1002359485 (9:129176668 C>A,T), RS1002394632 (9:129175928 T>G), RS1002834360 (9:129175652 G>A), RS1003085922 (9:129175190 G>A), RS1003629144 (9:129175438 C>A,T), RS1003801729 (9:129176746 G>C,T), RS1004382602 (9:129177465 C>A,G), RS1004399552 (9:129177579 C>A), RS1005253633 (9:129179484 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST006624_81	Systolic blood pressure	1.000000e-09
GCST007432_89	FEV1	3.000000e-09
GCST007576_129	Chronotype	3.000000e-11
GCST010083_77	Hemoglobin levels	1.000000e-09
GCST010143_23	Meat-related diet	6.000000e-11

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0004314	forced expiratory volume
EFO:0008328	chronotype measurement
EFO:0004509	hemoglobin measurement
EFO:0008111	diet measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression, decreases expression	5
Tetrachlorodibenzodioxin	increases expression	3
(+)-JQ1 compound	increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Estradiol	affects cotreatment, increases expression	2
Ethinyl Estradiol	affects expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	increases abundance, decreases expression	2
Tobacco Smoke Pollution	increases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
bisphenol A	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	affects expression	1
butyraldehyde	decreases expression	1
tobacco tar	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
cyanoginosin LR	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dimethylarsinous acid	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
licochalcone B	increases expression	1
MT19c compound	decreases expression	1
2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydropyrido(4,3-d)pyrimidin-5(6H)-one	increases activity, increases expression	1
theaflavin-3,3’-digallate	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.